Kidney transplant drug halves risk of rejection

Scientists have shown that a drug given at the time of a kidney transplant operation halves the early risk of kidney rejection and allows for a less toxic treatment.

The study recruited 852 patients who underwent a kidney transplant in the UK between 2010 and 2013. The study tested whether the drug alemtuzumab (an anti-rejection treatment) partnered with a low-dose of tacrolimus (a calcineurin inhibitor) could reduce transplant rejection when compared with existing treatment.

The findings will help guide kidney transplant treatments in the future.

Read more at University of Oxford